EPISODE · Mar 11, 2022 · 11 MIN
Mavenclad Works Best at Reducing Relapses & Managing Fatigue Through Medication
from MS News & Perspectives · host MS News Today
Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, covers how MS patients on Mavenclad are less likely to experience a disease relapse than those on other oral DMTs like Gilenya, Tecfidera, or Aubagio.He also reads “The Double-Edged Sword of Fatigue Medications”, from Beth Ullah's column "Through the Looking Glass".=================================== Are you interested in learning more about multiple sclerosis? If so, please visit:https://multiplesclerosisnewstoday.com/ =====================================To join in on conversations regarding multiple sclerosis, please visit:https://multiplesclerosisnewstoday.com/forums/
NOW PLAYING
Mavenclad Works Best at Reducing Relapses & Managing Fatigue Through Medication
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m